The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

Nature Communications

Volumn 5, Issue , 2014, Pages

  Wang, Wei ^a   Qin, Jiang Jiang ^a   Voruganti, Sukesh ^a   Srivenugopal, Kalkunte S ^a   Nag, Subhasree ^a   Patil, Shivaputra ^b   Sharma, Horrick ^b   Wang, Ming Hai ^a   Wang, Hui ^c   Buolamwini, John K ^b   Zhang, Ruiwen ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; CYTOTOXIC AGENT; INDOLE DERIVATIVE; LIGASE INHIBITOR; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; SP 141; UNCLASSIFIED DRUG; 6-METHOXY-1-(NAPHTHALEN-1-YL)-9H-PYRIDO(3,4-B)INDOLE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

CANCER; DISEASE PREVALENCE; GENE EXPRESSION; INHIBITION; INHIBITOR; NUMERICAL MODEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BRAIN; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; ENZYME DEGRADATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLUORESCENCE POLARIZATION; HEART; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; LUNG; MCF 7 CELL LINE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SPLEEN; THERAPY EFFECT; TUMOR XENOGRAFT; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; GENETICS; METABOLISM; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DESIGN; FEMALE; HUMANS; INDOLES; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84917732327     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6086     Document Type: Article

References (58)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014
2. DeSantis, C., Ma, J., Bryan, L. & Jemal, A. Breast cancer statistics, 2013. CA Cancer J. Clin. 64, 52-62 (2014
3. Lorusso, G. & Ruegg, C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin. Cancer Biol. 22, 226-233 (2012
4. Oakman, C., Santarpia, L. & Di Leo, A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat. Rev. Clin. Oncol. 7, 725-732 (2010
5. Marmot, M. G. et al. The benefits and harms of breast cancer screening: an independent review. Br. J. Cancer 108, 2205-2240 (2010
6. Turner, N. C. & Jones, A. L. Management of breast cancer-Part I. BMJ 337, 107-110 (2008
7. Turner, N. C. & Jones, A. L. Management of breast cancer-Part II. BMJ 337, 164-169 (2008
8. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2010
9. Carey, L., Winer, E., Viale, G., Cameron, D. & Gianni, L. Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7, 683-692 (2010
10. Turner, N. et al. Targeting triple negative breast cancer: is p53 the answer? Cancer Treat. Rev. 39, 541-550 (2013
11. Brekman, A., Singh, K. E., Polotskaia, A., Kundu, N. & Bargonetti, J. A p53- independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res. 13, R3 (2011
12. Boersma, B. J. et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J. Natl Cancer Inst. 98, 911-919 (2006
13. Santarius, T., Shipley, J., Brewer, D., Stratton, M. R. & Cooper, C. S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 10, 59-64 (2010
14. Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996
15. Zhang, Z. & Zhang, R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets 5, 9-20 (2005
16. Oliner, J. D. et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860 (1993
17. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997
18. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997
19. Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997
20. Bouska, A. & Eischen, C. M. Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem. Sci. 34, 279-286 (2009
21. Gu, L. et al. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 15, 363-375 (2009
22. Fu, W. et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J. Biol. Chem. 284, 13987-14000 (2009
23. Vlatkovic, N. et al. MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon. Nucleic Acids Res. 28, 3581-3586 (2000
24. Asahara, H. et al. Stimulation of human DNA polymerase epsilon by MDM2. Nucleic Acids Res. 31, 2451-2459 (2003
25. Soussi, T. & Beroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1, 233-240 (2001
26. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000
27. Shangary, S. & Wang, S. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 14, 5318-5324 (2008
28. Rayburn, E. R., Ezell, S. J. & Zhang, R. Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med. Chem. 9, 882-903 (2009
29. Li, Q. & Lozano, G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 19, 34-41 (2013
30. Zhang, R. & Wang, H. MDM2 oncogene as a novel target for human cancer therapy. Curr. Pharm. Des. 6, 393-416 (2000
31. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004
32. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328 (2004
33. Shangary, S. et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl Acad. Sci. USA 105, 3933-3938 (2008
34. Qin, J. J., Nag, S., Voruganti, S., Wang, W. & Zhang, R. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. Curr. Med. Chem. 19, 5705-5725 (2012
35. Shangary, S. & Wang, S. Small-molecule inhibitors of the MDM2-p53 proteinprotein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223-241 (2009
36. Rayburn, E., Zhang, R., He, J. & Wang, H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 5, 27-42 (2005
37. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 (2000
38. National Cancer Institute. SEER Stat Fact Sheets: Breast http://seer.cancer.gov/ statfacts/html/breast.html. Accessed 1 November (2013
39. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
40. Christiansen, J. J. & Rajasekaran, A. K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 66, 8319-8326 (2006
41. Knipscheer, P. & Sixma, T. K. Protein-protein interactions regulate Ubl conjugation. Curr. Opin. Struct. Biol. 17, 665-673 (2007
42. Dueber, E. C. et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376-380 (2011
43. Bai, L., Smith, D. C. & Wang, S. Small molecule SMAC mimetics as new cancer therapeutics. Pharmacol. Ther. 144, 82-95 (2014
44. Natt, F. siRNAs in drug discovery: target validation and beyond. Curr. Opin. Mol. Ther. 9, 242-247 (2007
45. Rayburn, E., Wang, H., He, J. & Zhang, R. RNA silencing technologies in drug discovery and target validation. Lett. Drug Des. Discov. 2, 1-18 (2005
46. Lukas, J. et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 61, 3212-3219 (2001
47. Jiang, M. et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer 74, 529-534 (1997
48. Kussie, P. H. et al. Crystal structure of the MDM2 oncoprotein bound to the transactivation domain of the p53 tumor suppressor. Science 274, 948-953 (1996
49. Zhang, Z. et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279, 16000-16006 (2004
50. Deng, W. G., Zhu, Y., Montero, A. & Wu, K. K. Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidinagarose pulldown assay. Anal. Biochem. 323, 12-18 (2003
51. Schon, O., Friedler, A., Bycroft, M., Freund, S. M. & Fersht, A. R. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323, 491-501 (2002
52. Ding, K. et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 127, 10130-10131 (2005
53. Chen, D. et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 26, 5029-5037 (2007
54. Wang, W. et al. In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin. Cancer Res. 15, 3511-3518 (2009
55. Wang, W. et al. A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action. Breast Cancer Res. Treat. 123, 321-331 (2010
56. Wang, W. et al. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS ONE 7, e41586 (2012
57. Zhang, X. et al. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene 32, 2782-2791 (2013
58. Zhang, X. et al. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J. Biol. Chem. 287, 30468-30476 (2012